Miranda Kirby1, Damien Pike1, Don D Sin1, Harvey O Coxson1, David G McCormack1, Grace Parraga1. 1. From the James Hogg Research Centre, the University of British Columbia and the Institute of Heart and Lung Health, St Paul's Hospital, Vancouver, BC, Canada (M.K., D.D.S., H.O.C.); Imaging Research Laboratories, Robarts Research Institute (D.P., G.P.), and Department of Medical Biophysics (D.P., G.P.) and Division of Respirology, Department of Medicine (D.G.M.), the University of Western Ontario, 1151 Richmond St N, London, ON, Canada N6A 5B7.
Abstract
PURPOSE: To determine the role of imaging measurements of emphysema and airway disease in determining chronic obstructive pulmonary disease (COPD) symptoms and exercise limitation in patients with COPD, particularly in patients with mild-to-moderate disease. MATERIALS AND METHODS: Participants (n = 116) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade U (unclassified) or grade I-IV COPD provided informed consent to an ethics board-approved HIPAA-compliant protocol and underwent spirometry and plethysmography, completed the St George's Respiratory Questionnaire (SGRQ), completed a 6-minute walk test for the 6-minute walk distance (6MWD), and underwent hyperpolarized helium 3 ((3)He) magnetic resonance (MR) imaging and computed tomography (CT). Emphysema was estimated by using the MR imaging apparent diffusion coefficient (ADC) and the relative area of the CT attenuation histogram with attenuation of -950 HU or less (RA950). Airway disease was measured by using the CT airway wall thickness of airways with an internal perimeter of 10 mm and total airway count. Ventilation defect percentage at (3)He MR imaging was used to measure ventilation. Multivariable regression models for the 6MWD and SGRQ symptom subscore were used to evaluate the relationships between physiologic and imaging measurements. RESULTS: Multivariate modeling for the 6MWD in 80 patients with GOLD grade U-II COPD showed that ADC (β = 0.34, P = .04), diffusing capacity of the lung for carbon monoxide (β = 0.60, P = .0008), and residual volume/total lung capacity (β = -0.26, P = .02) were significant variables, while forced expiratory volume in 1 second (FEV1) and airway disease measurements were not. In 36 patients with GOLD grade III or IV disease, FEV1 (β = 0.48, P = .01) was the only significant contributor in a multivariate model for 6MWD. MR imaging emphysema measurements also made the greatest relative contribution to symptoms in patients with milder (GOLD grade U-II) COPD (ADC: β = 0.60, P = .005; RA950: β = -0.52, P = .02; FEV1: β = -0.45, P = .0002) and in grade III or IV disease (ADC: β = 0.95, P = .01; RA950: β = -0.62, P = .07; airway count: β = -0.49, P = .01). CONCLUSION: In patients with mild-to-moderate COPD, MR imaging emphysema measurements played a dominant role in the expression of exercise limitation, while both CT and MR imaging measurements of emphysema explained symptoms.
PURPOSE: To determine the role of imaging measurements of emphysema and airway disease in determining chronic obstructive pulmonary disease (COPD) symptoms and exercise limitation in patients with COPD, particularly in patients with mild-to-moderate disease. MATERIALS AND METHODS:Participants (n = 116) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade U (unclassified) or grade I-IV COPD provided informed consent to an ethics board-approved HIPAA-compliant protocol and underwent spirometry and plethysmography, completed the St George's Respiratory Questionnaire (SGRQ), completed a 6-minute walk test for the 6-minute walk distance (6MWD), and underwent hyperpolarized helium 3 ((3)He) magnetic resonance (MR) imaging and computed tomography (CT). Emphysema was estimated by using the MR imaging apparent diffusion coefficient (ADC) and the relative area of the CT attenuation histogram with attenuation of -950 HU or less (RA950). Airway disease was measured by using the CT airway wall thickness of airways with an internal perimeter of 10 mm and total airway count. Ventilation defect percentage at (3)He MR imaging was used to measure ventilation. Multivariable regression models for the 6MWD and SGRQ symptom subscore were used to evaluate the relationships between physiologic and imaging measurements. RESULTS: Multivariate modeling for the 6MWD in 80 patients with GOLD grade U-IICOPD showed that ADC (β = 0.34, P = .04), diffusing capacity of the lung for carbon monoxide (β = 0.60, P = .0008), and residual volume/total lung capacity (β = -0.26, P = .02) were significant variables, while forced expiratory volume in 1 second (FEV1) and airway disease measurements were not. In 36 patients with GOLD grade III or IV disease, FEV1 (β = 0.48, P = .01) was the only significant contributor in a multivariate model for 6MWD. MR imaging emphysema measurements also made the greatest relative contribution to symptoms in patients with milder (GOLD grade U-II) COPD (ADC: β = 0.60, P = .005; RA950: β = -0.52, P = .02; FEV1: β = -0.45, P = .0002) and in grade III or IV disease (ADC: β = 0.95, P = .01; RA950: β = -0.62, P = .07; airway count: β = -0.49, P = .01). CONCLUSION: In patients with mild-to-moderate COPD, MR imaging emphysema measurements played a dominant role in the expression of exercise limitation, while both CT and MR imaging measurements of emphysema explained symptoms.
Authors: Jie Yang; Elsa D Angelini; Pallavi P Balte; Eric A Hoffman; Colin O Wu; Bharath A Venkatesh; R Graham Barr; Andrew F Laine Journal: Med Image Comput Comput Assist Interv Date: 2016-10-02
Authors: David G Mummy; Stanley J Kruger; Wei Zha; Ronald L Sorkness; Nizar N Jarjour; Mark L Schiebler; Loren C Denlinger; Michael D Evans; Sean B Fain Journal: J Allergy Clin Immunol Date: 2017-11-10 Impact factor: 10.793
Authors: Esther Pompe; Craig J Galbán; Brian D Ross; Leo Koenderman; Nick Ht Ten Hacken; Dirkje S Postma; Maarten van den Berge; Pim A de Jong; Jan-Willem J Lammers; Firdaus Aa Mohamed Hoesein Journal: Respir Med Date: 2016-11-25 Impact factor: 3.415
Authors: Carlos H Martinez; Alejandro A Diaz; Catherine Meldrum; Jeffrey L Curtis; Christopher B Cooper; Cheryl Pirozzi; Richard E Kanner; Robert Paine; Prescott G Woodruff; Eugene R Bleecker; Nadia N Hansel; R Graham Barr; Nathaniel Marchetti; Gerard J Criner; Ella A Kazerooni; Eric A Hoffman; Brian D Ross; Craig J Galban; Christine T Cigolle; Fernando J Martinez; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2017-02-15 Impact factor: 21.405
Authors: David G Mummy; Katherine J Carey; Michael D Evans; Loren C Denlinger; Mark L Schiebler; Ronald L Sorkness; Nizar N Jarjour; Sean B Fain Journal: J Allergy Clin Immunol Date: 2020-03-13 Impact factor: 10.793
Authors: Ivan Dudurych; Susan Muiser; Niall McVeigh; Huib A M Kerstjens; Maarten van den Berge; Marleen de Bruijne; Rozemarijn Vliegenthart Journal: Eur Radiol Date: 2022-02-22 Impact factor: 7.034
Authors: Ozkan Doganay; Tahreema Matin; Mitchell Chen; Minsuok Kim; Anthony McIntyre; Daniel R McGowan; Kevin M Bradley; Thomas Povey; Fergus V Gleeson Journal: Eur Radiol Date: 2018-12-14 Impact factor: 5.315
Authors: Christopher B Cooper; Robert Paine; Jeffrey L Curtis; Richard E Kanner; Carlos H Martinez; Catherine A Meldrum; Russell Bowler; Wanda O'Neal; Eric A Hoffman; David Couper; Miguel Quibrera; Gerald Criner; Mark T Dransfield; MeiLan K Han; Nadia N Hansel; Jerry A Krishnan; Stephen C Lazarus; Stephen P Peters; R Graham Barr; Fernando J Martinez; Prescott G Woodruff Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-08-04
Authors: Benjamin M Smith; Dennis Jensen; Marc Brosseau; Andrea Benedetti; Harvey O Coxson; Jean Bourbeau Journal: Sci Rep Date: 2018-10-24 Impact factor: 4.379